TORONTO, ON / ACCESSWIRE / October 27, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX Venture: TLT) (PINKSHEETS: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its latest anti-cancer technology research, combining Photo Dynamic Compounds ("PDCs") with a naturally occurring glycoprotein, transferrin, and activating the combination with a specific wavelength of light has been published in Photodiagnosis and Photodynamic Therapy.
Photodiagnosis and Photodynamic Therapy is an international journal focused on the dissemination of scientific knowledge and clinical developments pertaining to the use of light and PDCs in the diagnosis and treatment of numerous medical conditions, across all medical specialties.
Photodynamic therapy ("PDT") uses the combination of a PDC and a specific wavelength of light to produce cell-killing molecules, such as Reactive Oxygen Species ("ROS") to destroy the intended cellular target, thus proving to be a promising avenue for non-invasive cancer treatment.
The novel Theralase PDC, TLD-1433, has previously shown efficacy in the destruction of microbial and cancerous tumours during preclinical in-vivo (animal) and in-vitro (cellular) studies.
In Theralase's latest research, the binding of TLD-1433 with a naturally occurring glycoprotein, transferrin, results in further enhancements of TLD-1433's properties as an effective anti-cancer agent.
When TLD-1433 is bound to transferrin, the combination results in:
- Increased: absorption in the green light spectrum (greater efficacy for superficial tumours)
- Increased absorption in the red and near infrared light spectrum (greater efficacy for deeper set tumours)
- Increased bleaching resistance (minimal loss in potency over time)
- Increased ROS production (increased efficacy)
- Reduced dark toxicity (no effect until light activated)
- Increased PDT mediated cell kill (increased efficacy)
- Increased tumour free survival time of mice compared to TLD1433 alone at identical light doses (enhanced efficacy)
Roger Dumoulin-White, President and CEO, Theralase stated that, "The acceptance of Theralase's latest research for publication in a well-regarded international journal underlines the importance that the scientific community places on this cutting-edge technology. The TLC-3000 anti-cancer technology is on track to commence enrolling patients in late 4Q2015 to determine the safety, tolerability and efficacy in the destruction of Non-Muscle Invasive Bladder Cancer. In combination with transferrin, Theralase's lead PDC increases the efficacy that this technology has on the destruction of a wide range of cancers."
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase(R)") (TSX Venture: TLT) (PINKSHEETS: TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
SOURCE: Theralase Technologies Inc.